Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants

Immunogenicity and safety of currently available Japanese encephalitis vaccines: A systematic review

“…Erra et al 47 conducted a study among travelers to estimate whether IXIARO can be used to boost immunity after a primary series of MBJEV. In travelers primed with MBJEV, vaccination response rates after a booster dose of MBJEV or IXIARO were 91% and 98% for the Nakayama strain, respectively, while 91% and 95% for SA14-14-2 strain, respectively.…”

Japanese Encephalitis: Epidemiology and Current Perspectives in Vaccines

“…A large randomised controlled trial in China with 26,239 subjects (13,266 vaccinated children) showed similar relative risk of adverse events (hospitalisation, seizures, fever) in the vaccinated and unvaccinated groups after 30 days follow up and no severe adverse or neurological events were observed [68]. Two further studies including one in South Korea have shown no severe adverse events and a low rate of mild events-fever, rash, irritability loss of appetite in around 10% [66] 3 . The most recent experience with surveillance following large scale vaccination in India showed a low rate of SAEs, with most considered unrelated to vaccination and due to background morbidity and mortality [61].…”

“…So far the vaccine has remained attenuated in animal studies and viraemia induced by vaccination is likely to be below threshold for infection to mosquitos [29]. Furthermore, the vaccine has a good safety and efficacy record in clinical studies (Table 3) [13,[61][62][63][64][65][66][67][68][69][70][71].…”

Japanese Encephalitis Virus: Innate and Adaptive Immunity

“…SA14-14-2 was licensed in china in 1988 and provides 80-96% protection after a single dose and further studies in China have shown 97.5% efficacy after 2 doses 1 year apart (Tandan et al, 2007;Hennessy et al, 1996;Xin et al, 1988). Seroconversion of 99-100% and neutralizing antibody titres of 1:50 to 1:150 has been observed in field trials with this vaccine in China and South Korea (Tsai, 2000;Sohn et al, 1999;Tsai et al, 1999). Very few side effects were observed.…”